You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
PTH, INTRAOPERATIVE |
||
Geisinger Epic Procedure Code: LAB2953
Geisinger Epic ID: 33401
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Plasma | |
Preferred collection container: |
||
Specimen required: |
5 mL; minimum 2 mL. | |
Special notes: |
This test is performed on intraoperative patients only. In patients receiving high biotin doses (i.e. >5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration. | |
Patient preparation: |
This test is performed stat on intraoperative patients only. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge to separate plasma within 2 hours of collection. | |
Transport temperature: |
Refrigerated or frozen. | |
Specimen stability: |
Room temperature: 2 days. Refrigerated: 3 days. Frozen: 6 months. | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Reference interval: |
15-65 pg/mL | |
Critical values/courtesy alerts: |
All results phoned to operating room. | |
Additional information: |
Intraoperative specimens performed stat. | |
CPT code(s): |
83970 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Rapid parathyroid hormone. | |
Methodology: |
Electrochemiluminescence Immunoassay |
|
Synonyms: |
PARATHYROID HORMONE, INTACT RAPID PTH, PTH, INTRAOPERATIVE PTH PTHR
|
|
Clinical significance: |
The major function of PTH is to maintain the serum total calcium within a narrow range. The net effects of PTH are to increase the serum concentration of calcium and to decrease that of phosphate. The assay is useful in making the diagnosis of primary hyperparathyroidism, secondary hyperparathyroidism, and a differential diagnosis of hypercalcemia. The assay helps in distinguishing hypercalcemia caused by either primary hyperparathyroidism or malignant disease. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 12/14/2022 | |